What are the side effects of Revumenib-Revuforj?

Revuforj (Revumenib)-Revuforj is an innovative oral drug approved by the FDA for the treatment of relapsed or refractory acute leukemias carrying lysine methyltransferase 2A gene (KMT2A) translocation, including acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). Because of its unique mechanism of action, it directly inhibits the abnormal epigenetic pathway driven by mixed lineage leukemia1 (MLL1, also known as KMT2A) rearrangement, so it has shown significant efficacy in certain high-risk groups. However, similar to all targeted anti-cancer drugs, Rivimenib will also be accompanied by certain adverse reactions during the treatment process.

In clinical observations, the most common side effects of Revimenib include nausea, vomiting, loss of appetite, and fatigue. Most of these symptoms are mild to moderate, and patients can be improved through dietary adjustments, drug assistance, and regular work and rest. In addition, some patients will experience hematological adverse reactions such as anemia, thrombocytopenia or leukopenia, which are related to the drug's suppressive effect on bone marrow and require regular hematological monitoring during treatment.

Of particular concern, revimenib may cause differentiation syndrome, a serious complication common with targeted leukemia drugs. This syndrome manifests as fever, dyspnea, hypotension, fluid retention, and organ dysfunction. Once present, medication should be discontinued immediately and glucocorticoid intervention should be used. When doctors prescribe revimenib, they usually inform patients of the risks in advance and establish a monitoring plan.

In addition, some patients may experience elevated liver function indicators, arrhythmia, or electrolyte imbalance, so liver function and electrocardiogram need to be checked regularly during medication. Although these side effects may not occur in every patient, given that the overall physical condition of leukemia patients is relatively fragile, timely identification and management of adverse reactions is an important step in ensuring efficacy and safety.

Reference materials:https://www.drugs.com/monograph/revumenib.html